Today: 21 May 2026
Browse Category

NASDAQ:VRNS 29 October 2025 - 24 February 2026

Varonis stock rebounds after 11% slide as fresh shareholder lawsuit filing hits tape

Varonis stock rebounds after 11% slide as fresh shareholder lawsuit filing hits tape

Varonis Systems shares rose about 2.4% to $21.59 Tuesday morning after plunging 11% the previous day. A law firm said a securities class action was filed for investors who bought between Feb. 4 and Oct. 28, 2025, with a lead-plaintiff deadline set for March 9. The company remains under scrutiny as it shifts to SaaS subscriptions and faces a projected $30–$50 million 2026 revenue hit from government clients not converting.
24 February 2026
··
Varonis Systems (VRNS) stock jumps 8% as Cantor trims target, SaaS shift back in focus

Varonis Systems (VRNS) stock jumps 8% as Cantor trims target, SaaS shift back in focus

Varonis shares rose 8.3% to $36.06 by midday Wednesday, outpacing the Nasdaq’s 0.7% gain. Cantor Fitzgerald cut its price target to $50 from $60 but maintained an Overweight rating, citing SaaS growth and strong net revenue retention. Investors are watching early February results for signs of recurring revenue and churn. The stock remains down nearly 35% over six months.
7 January 2026
··
Varonis Stock Plummets 45% After Weak Q3 Earnings – Analysts React to Shock Guidance Cut

Varonis Stock Plummets 45% After Weak Q3 Earnings – Analysts React to Shock Guidance Cut

Varonis Systems shares plunged about 45% on October 29, closing near $34 after Q3 revenue missed estimates and the company slashed its outlook. Management cited a late-quarter slowdown and plans to phase out on-premises products by 2026. The board approved a $150 million buyback and a 5% workforce cut. Analysts cut price targets, with at least one downgrade, as the stock’s steep drop erased much of its 2025 gains.
29 October 2025
··

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop